Navigation Links
Wide disparities in access to latest rheumatoid arthritis drugs across Europe
Date:3/6/2013

This means that 320 million people - 40% of Europe's population - who could benefit from treatment with disease modifying drugs (DMARDs) would struggle to get access to them, say the researchers.

DMARDs are extremely effective for the treatment of rheumatoid arthritis, and the European League Against Rheumatism (EULAR) recommends the use of synthetic DMARDs immediately after diagnosis to halt progress of the disease. But they are expensive.

The authors therefore surveyed key experts in 49 countries during 2011 about the availability, affordability and acceptability of both synthetic DMARDs, such as methotrexate and leflunomide, and biological DMARDs, such as infliximab and etanercept.

In all, 46 countries took part in the survey, which included those in Eastern Europe, Scandinavia, and Western Europe, as well as Turkey and Uzbekistan.

The responses revealed wide disparities in access to DMARDs. Six countries did not reimburse use of any of the five synthetic DMARDs included in the survey, and 10 countries did not pay for any biological DMARDs.

The cost of one year's treatment with a synthetic DMARD did not exceed any country's per capita GDP). But the cost of one year's treatment with a biological DMARD was higher than the per capita GDP of 26 countries, by as much as 11 times, the findings indicated.

That means that almost 40% of the population of Europe - equivalent to 320 million people - would have severely restricted access to biological DMARDs, say the authors.

Access was especially poor in countries in Central and Eastern Europe and those least well off, economically and socially, the findings showed.

The number of days a person on an average income would need to work to pay fhe full drug price of 30 days' treatment with a biological DMARD ranged from 12 days in Luxembourg to 190 in Romania.

Although it's not possible to draw definitive conclusions on the impact on health of restricted access, higher drugs prices were associated with increased disease activity and poorer physical functioning.

"Assuming needs for treatment with DMARDs are similar across countries, differences in access to medical treatment are unfair and raise alarming issues of inequity," write the authors.

Wealthy Western countries continually debate the budgetary impact of expensive drugs, but unaffordability in low income countries is rarely discussed, they note.

The cheap cost of labour means that these expensive drugs are rarely going to be considered a return on investment, in terms of improved productivity, they add, and drug pricing in Europe should be revised, say the authors.


'/>"/>

Contact: Emma Dickinson
edickinson@bmjgroup.com
44-020-738-36529
BMJ-British Medical Journal
Source:Eurekalert

Related medicine news :

1. Praeclarus Press Launches the One Every 21 Seconds Campaign to Increase Awareness on the Role of Breastfeeding in Reducing Racial/Ethnic Disparities in Infant Mortality
2. Hospital Type Linked to Racial Disparities in Kids With Appendicitis Complication
3. Study reports racial disparities in pediatric appendicitis treatment tied to hospital type
4. Racial Disparities Still Seen in Use of Breast Cancer Treatments
5. Are there racial disparities in osteoporosis screening and treatment?
6. Policy considerations pose options for leaders to reduce costly disparities in diabetes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Orange County partnership to target cancer health disparities
9. Ethnic disparities in breast cancer survival remain despite socioeconomic similarities
10. AACR, Komen for the Cure honor researcher with lecture on science of cancer health disparities
11. Vanderbilt-led study reveals racial disparities in prostate cancer care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... (PRWEB) , ... May 21, 2017 , ... ... if it's been longer than six months since you've seen a dentist, it's ... twice per year and getting x-rays once per year. , Dental checkups are ...
(Date:5/19/2017)... ... May 19, 2017 , ... When Kyle Busch graduates from ... will already appear on two major research studies that could impact the health of ... Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team trying to ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Arnold ... Young Investigators: , Victor Acosta, Ph.D. - University of New Mexico, Jeremy Baskin, ... - University of Washington, Erik Grumstrup, Ph.D. - Montana Stata University, A. Fatih ...
(Date:5/19/2017)... ... 2017 , ... CloSYS products which are marketed as the gentle giants of ... and gum health, which is linked to one’s overall health. Since 1991 when the ... powerful ways in which CloSYS products immediately helped eliminate bad breath as well as ...
(Date:5/18/2017)... ... ... Originally launched to market as the EPIK Learning Tab, the highly successful ... of their product line, the company believed it was the right time to create ... be any tablet product sold by EPIK Learning. This year there will be ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
Breaking Medicine Technology: